Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01138306|
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from young patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: mutation analysis Other: flow cytometry Other: laboratory biomarker analysis|
- Determine the extent and prognostic implications of variable s-SHIP expression and SHIP gene mutations in pediatric patients with acute myeloid leukemia.
- Determine the effects of aberrant s-SHIP expression on the PI3K/Akt pathway in these patients via electrochemiluminescence and phosphospecific flow cytometry assays.
OUTLINE: RNA samples are analyzed for variable s-SHIP expression and are screened for SHIP mutations. Cryopreserved cells (with known high- or low-s-SHIP expression) are analyzed for the levels of various components of the PI3K/Akt pathway via electrochemiluminescence and phosphospecific flow cytometry.
|Study Type :||Observational|
|Estimated Enrollment :||149 participants|
|Observational Model:||Case Control|
|Official Title:||Implications of s-SHIP Expression and SHIP Alterations in AML|
|Study Start Date :||February 2013|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Event-free survival
- Overall survival
- Relapse rate
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138306
|Principal Investigator:||Phoenix Ho, MD||Fred Hutchinson Cancer Research Center|